| Literature DB >> 23738519 |
Regina Makdissi1, Scott H Stewart.
Abstract
There is increasing emphasis on screening, brief intervention, and referral to treatment (SBIRT) for unhealthy alcohol use in the general hospital, as highlighted by new Joint Commission recommendations on SBIRT. However, the evidence supporting this approach is not as robust relative to primary care settings. This review is targeted to hospital-based clinicians and administrators who are responsible for generally ensuring the provision of high quality care to patients presenting with a myriad of conditions, one of which is unhealthy alcohol use. The review summarizes the major issues involved in caring for patients with unhealthy alcohol use in the general hospital setting, including prevalence, detection, assessment of severity, reduction in drinking with brief intervention, common acute management scenarios for heavy drinkers, and discharge planning. The review concludes with consideration of Joint Commission recommendations on SBIRT for unhealthy alcohol use, integration of these recommendations into hospital work flows, and directions for future research.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23738519 PMCID: PMC3679958 DOI: 10.1186/1940-0640-8-11
Source DB: PubMed Journal: Addict Sci Clin Pract ISSN: 1940-0632
Selected findings on brief screening tools for unhealthy alcohol use
| AUDIT-C | ≥ 4 (men) | 86 (80-92) men | 89 (85-93) men | Primary care [ |
| (3 items)* | ≥ 3 (women) | 73 (66-79) women | 91 (89-93) women | |
| Quantity-Frequency | Exceeding recommended | 88 (83-94) men | 84 (80-89) men | Primary care [ |
| (3 items)* | drinking limits | 68 (61-75) women | 91 (89-93) women | |
| Heavy-drinking day | Any heavy days (≥ 4 drinks women, ≥ 5 drinks men) | 83 (71-90) men | 72 (61-81) men | Primary care [ |
| past year (1 item) | 81 (64-91) women | 84 (76-89) women |
*The AUDIT-C and quantity-frequency items were identical, with different interpretations of a positive result.
Selected findings on brief screening tools for alcohol use disorders
| AUDIT | ≥ 8 | Range | Range | Systematic review of primary care studies [ |
| (10 items)* | 61 to 96 | 85 to 96 | ||
| CAGE | ≥ 2 | Range | Range | Systematic review of primary care studies [ |
| (4 items) | 77 to 94 | 79 to 97 | ||
| RAPS4 | ≥ 1 | 93 | 87 | Emergency department patients [ |
| (4 items) | ||||
*AUDIT includes the AUDIT-C and can be used to screen for unhealthy alcohol use. Similarly, screens in Table 1 can be combined with screens in Table 2 to jointly screen for unhealthy alcohol use and alcohol use disorders.
American Psychiatric Association criteria for alcohol use disorders
| (≥ 3 of the following) | (≥ 1 of the following) | (≥ 2 of the following) |
|---|---|---|
| • Tolerance | • Tolerance | |
| • Withdrawal | • Withdrawal | |
| • Repeatedly exceeding intended limits | • Increased risk for physical harm | • Repeatedly exceeding intended limits |
| • Spending a lot of time drinking or recovering from alcohol effects | • Trouble in important relationships | • Spending a lot of time drinking or recovering from alcohol effects |
| • Failed attempts to cut down or abstain | • Failure to perform important roles | • Failed attempts to cut down or abstain |
| • Continued drinking despite physical or psychological problems | • Legal problems* | • Continued drinking despite physical or psychological problems |
| • Spending less time on important activities due to drinking | | • Spending less time on important activities due to drinking |
| | | • Increased risk for physical harm |
| | | |
| | | • Trouble in important relationships |
| | | • Failure to perform important roles |
| • Craving for alcohol* |
*“Legal problems” will be dropped as an alcohol use disorder criterion, and “craving” will be added.
Immediate issues in the care of chronic heavy drinkers admitted to the hospital
| Assess risk for nutritional deficiency | • Thiamine supplementation. |
| • Possibly folate and multivitamin supplement. | |
| Assess hydration status and electrolytes (risk for hypocalcemia and hypomagnesemia with or without hypokalemia and hypophosphatemia) | • IV or oral fluids. |
| • Oral or IV electrolyte replacement. | |
| Risk for acute alcohol withdrawal | • Close observation with validated instrument or prophylactic benzodiazepine, particularly in those with previous withdrawals or history of severe withdrawal (delirium tremens or seizure). |
| • Prophylaxis still requires close observation for over or under-sedation. | |
| Active alcohol withdrawal | • Symptom-triggered or scheduled benzodiazepine. |
| • Close observation with validated instrument with either symptom-triggered or scheduled dosing. | |
| • Alternate medication (e.g., phenobarbital) in rare event that benzodiazepine is unsuccessful at controlling agitation. | |
| • Possible beta blocker or clonidine for autonomic manifestations if benzodiazepine alone is insufficient. | |
| • Possible haloperidol if benzodiazepine alone is insufficient for delirium. | |
| • Consider other causes of delirium. |
Examples of symptom-triggered regimens for alcohol withdrawal*†
| Diazepam 10 to 20 mg if CIWA-Ar ≥ 8 to 10 | Repeat same dose hourly until | Long half-life may provide smoother withdrawal, but may accumulate in elderly or those with liver disease. |
| CIWA-Ar < 10 | ||
| Chlordiazepoxide 50 mg if CIWA-Ar > 9 | Repeat 50 mg hourly until CIWA-Ar < 10 | Intermediate half-life may provide smoother withdrawal than lorazepam. |
| Lorazepam 2 to 4 mg if CIWA-Ar ≥ 8 to 10 | Repeat same dose hourly until | Short half-life may increase withdrawal symptoms between doses. May be better tolerated in elderly and liver disease patients. |
| CIWA-Ar < 10 |
*Fixed dose regimens generally consist of the same dose administered every 6 hours for 24 hours followed by half the initial dose every 6 hours for 48 hours. Close monitoring is still critical as adjustments in dose, frequency, and length of taper depend on clinical response.
†Detailed descriptions are found in citations 48 and 53.
Select Effects of Medications on Drinking Outcomes
| Naltrexone | Heavy drinking day (≥ 60 grams alcohol) | Relative risk 0.83 | Meta-analysis of 50 | Avoid in patients with opioid abuse or use; caution in liver disease and advanced kidney disease |
| (0.76-0.90) | randomized controlled trial (RCT’s) [87] | |||
| Acamprosate | Any drinking | Relative risk 0.86 | Meta-analysis of 24 | Avoid with advanced kidney disease |
| (0.81-0.91) | RCT’s [86] | |||
| Disulfiram | Any drinking | Slight majority of trials found improved abstinence. | Review of 11 RCT’s [85] | Avoid if alcohol-disulfiram reaction medically dangerous; number of medical conditions associated with accidental reaction; avoidance of alcohol-containing products |
| Topiramate* | % heavy drinking days | 8.4% reduction | Multicenter RCT [83] | Caution with advanced liver or kidney disease; risk for metabolic acidosis with predisposing conditions; avoid abrupt discontinuation |
| (3.1-13.8) | ||||
| Ondansetron* | Average number of drinks on days alcohol was consumed | RCT [84] | Not shown to be beneficial for later-onset alcohol dependence; may prolong QT interval |
*Not FDA-approved for treating alcohol dependence.
Potential research topics relevant to patient care and JCAHO quality measures
| Screening and assessment | •Is there reason to use more than a single heavy drinking day question to screen for unhealthy alcohol use? |
| •Is there a better strategy than screening all admissions? | |
| •How should screening be integrated with electronic work flows? | |
| •What is the role of newer alcohol consumption biomarkers? | |
| •What is the optimal assessment method in the hospital? | |
| •What training will hospital-based clinicians require to enhance their skills and confidence in diagnosing alcohol use disorders? | |
| •How do patients feel about assessment during hospitalization? | |
| Treatment | •What patients are most likely to respond to brief intervention? |
| •How can the beneficial effects of brief intervention on alcohol use be increased? | |
| •How do we enhance the success of referral? | |
| •Does pharmacotherapy for relapse prevention work in this population? | |
| •What is the role for joint detection and treatment of other drug and mental health co-morbidities? | |
| •Can computerized support enhance treatment? | |
| Measuring performance | •What are the effects of brief intervention on other outcomes such as progression of alcohol problems and hospital readmission? |
| •What are the most pertinent patient-centered outcomes? | |
| •What is the optimal method for assessing the quality of hospital-based SBIRT? |